Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis

By  

Nephron Clin Pract, Vol. 121, Iss. 3-4, 2012-11 ,pp. : c95-c101

Karger

Access to resources Recommend Favorite

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Effect of Erythropoiesis-Stimulating Agents in Patients with Therapy-Refractory Autoimmune Hemolytic Anemia

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 6, 2014-09 ,pp. : 462-468

Karger

Access to resources Recommend Favorite

Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

By Dean Bonnie B.   Dylan Michelle   Gano Anacleto   Knight Kevin   Ofman Joshua J.   Levine Barton S.  

Current Medical Research and Opinion, Vol. 21, Iss. 7, 2005-07 ,pp. : 981-988

Informa Healthcare

Access to resources Recommend Favorite

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2329-2336

Informa Healthcare

Access to resources Recommend Favorite